0.34 CNY
40.06 M CNY
492.71 M CNY
84.78 M
About GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY
Sector
Industry
CEO
Xiang Ting Cai
Website
Headquarters
Guangzhou
Founded
2005
ISIN
CNE1000043R4
FIGI
BBG0083397X1
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. Its products include cytological, immunohistochemical, and molecular diagnostic reagents and instruments. The company was founded by Xiang Ting Cai on July 6, 2005 and is headquartered in Guangzhou, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 688393 is 19.62 CNY — it has increased by 0.10% in the past 24 hours. Watch GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY stocks are traded under the ticker 688393.
688393 stock has fallen by −1.80% compared to the previous week, the month change is a 8.22% rise, over the last year GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY has showed a −27.73% decrease.
688393 reached its all-time high on Aug 20, 2020 with the price of 74.00 CNY, and its all-time low was 12.83 CNY and was reached on Feb 8, 2024. View more price dynamics on 688393 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
688393 stock is 3.16% volatile and has beta coefficient of 1.26. Track GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY stock price on the chart and check out the list of the most volatile stocks — is GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY there?
Today GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY has the market capitalization of 1.83 B, it has increased by 2.24% over the last week.
Yes, you can track GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY financials in yearly and quarterly reports right on TradingView.
688393 net income for the last quarter is 13.27 M CNY, while the quarter before that showed 8.37 M CNY of net income which accounts for 58.46% change. Track more GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY financial stats to get the full picture.
Yes, 688393 dividends are paid annually. The last dividend per share was 0.15 CNY. As of today, Dividend Yield (TTM)% is 0.77%. Tracking GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY dividends might help you take more informed decisions.
GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY dividend yield was 0.60% in 2023, and payout ratio reached 35.00%. The year before the numbers were 0.64% and 30.61% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 907.00 employees. See our rating of the largest employees — is GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY on this list?
Like other stocks, 688393 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY stock shows the sell signal. See more of GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.